Azilsartan

Drugbox
IUPAC_name = (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-( [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl] methyl)-1H-benzimidazole-7-carboxylate

---

CAS_number = 863031-21-4
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem =
DrugBank =
chemical_formula =
C=30 | H=24 | N=4 | O=8
molecular_weight = 568.5
smiles = Cc2oc(=O)oc2COC(=O)c4c1c(ccc4)nc(OCC)n1Cc(cc6)ccc6-c3ccccc3-c5nc(=O)on5
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Azilsartan (rINN; codenamed TAK-491) is an angiotensin II receptor antagonist undergoing research for the treatment of hypertension.

It was developed by Takeda. As of 2008, Takeda is currently conducting phase III clinical trials. [cite web |url=http://www.clinicaltrials.gov/ct2/results?term=Azilsartan |title=Complete list of clinical trials for azilsartan (ClinicalTrials.gov) |format= |work= |accessdate=2008-06-20]

References